Journal of the European Society for Gynaecological Endoscopy


Corifollitropin stimulation in combination with GnRH-antagonists after estradiol valerate pre-treatment. A pilot study on patient-friendly IVF

W. Decleer1, K. Verschueren2, S. Vandeginste3, K. Osmanagaoglu1, P. Devroey1

1Fertility center, AZ Jan Palfijn Hospital, Henri Dunantlaan 5, 9000 Gent, Belgium.

2Living Statistics, Kunstenaarstraat 35, 9040 Sint-Amandsberg, Belgium.

3OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium.

Correspondence at: Wim Decleer, AZ Jan Palfijn, Henri Dunantlaan 5, 9000 Gent, Belgium. E-mail:


Scheduling, Corifollitropin Alfa, agonist-triggering, IVF, Progynova pre-treatment, patient-friendly IVF.

Published online: Jan 11 2016


Objective: To demonstrate the feasibility of scheduling an IVF cycle, without disadvantages, in the new patient friendly stimulation protocol using the long acting Corifollitropin Alfa, in combination with GnRH-antagonist protection and GnRH-agonist triggering. Study design: Two groups of ten patients were admitted in the study. Both received the same stimulation protocol with Corifollitropin Alfa in combination with GnRH-antagonist protection. After ultrasound evaluation on day 7 individually dosed Menopur was added. For triggering final oocyte maturation GnRH-agonists were used. The only difference between the two groups was that in the study group, estradiol valerate 4 mg/day was given from day 25 of the preceding cycle for a period of 10 days, thus postponing the start of follicular growth. Results: Scheduling the IVF stimulation by the administration of estradiol valerate 4 mg/day did not influence the hormonal curves, nor the embryological results in comparison to patients with the same stimulation, starting their stimulation at the beginning of menstruation. In this pilot study four out of ten patients turned out to be pregnant, demonstrating an acceptable pregnancy rate. Conclusion: The combination of estradiol valerate 4 mg/day pre-treatment with the novel combination of Corifollitropin Alfa stimulation with GnRH-antagonist protection, individually topped off with Menopur, and triggered with GnRH-agonist proved to be a safe, patient-friendly (limited number of injections in comparison to classical IVF) (Patil, 2014) and efficient alternative to classical IVF stimulation protocols, allowing patients – and doctors – to schedule the treatment cycle to their convenience.